GenEndeavor — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $5M

Overview

GenEndeavor is a private, pre-revenue diagnostics company developing a proprietary Non-Enzymatic Amplification Technologies (NEAT) platform aimed at revolutionizing molecular diagnostics. The company's initial focus is on creating an accessible diagnostic tool for the early detection of ovarian cancer, with a broader vision to impact genetic diseases, infectious diseases like tuberculosis, and agricultural trait screening. Led by founder and CEO Ricardo Mancebo, the company is actively engaging with investors and global partners to advance its technology and pipeline.

OncologyInfectious Disease

Technology Platform

Non-Enzymatic Amplification Technologies (NEAT) platform for sensitive, rapid, and affordable point-of-care molecular diagnostics.

Funding History

1

Total raised:$5M

Seed$5MUndisclosedAug 15, 2022

Opportunities

The global push for decentralized, point-of-care diagnostics and the critical unmet need for early ovarian cancer screening present a massive market opportunity.

Success with its NEAT platform could also enable expansion into other disease areas and agricultural applications.

Risk Factors

Key risks include the technical validation of a novel non-enzymatic amplification platform, navigating regulatory pathways for clinical diagnostics, and competing in a crowded market while reliant on external funding as a pre-revenue company.

Competitive Landscape

GenEndeavor competes in the molecular diagnostics space against large established players (e.g., Roche, Abbott, Qiagen) and numerous startups developing point-of-care nucleic acid tests. Its differentiation hinges on the potential cost, simplicity, and performance advantages of its non-enzymatic NEAT platform.

More companies in Diagnostics & Precision Medicine →More companies in United States →